Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


Press Release: Government decision on cannabis-related medicinal products draws criticism from independent scientific body, Drug Science.

Today (13th August 2019), the independent scientific body Drug Science has responded with disappointment to a decision by the National Institute for Health and Care Excellence (NICE), relating to cannabis-related medical products. In November 2018, the then Home Secretary Sajid Javid introduced regulations so that cannabis-derived medicinal products would be available on prescription. This change  …


First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed the full 8-week MDMA-assisted  …


Drug Science gives evidence to the Health and Social Care Committee on Medicinal Cannabis

On 1 November 2018, following considerable popular pressure surrounding a select number of young children with treatment-resistant epilepsy who responded well to medicinal cannabis (and medicinal cannabis alone), regulations in the UK came into force to reschedule cannabis‑derived medicinal products to schedule 2 of the Misuse of Drugs Regulations 2001 and to allow prescribing of  …

Drug Science gives evidence to the Health and Social Care Committee on Medicinal Cannabis

On 1 November 2018, following considerable popular pressure surrounding a select number of young children with treatment-resistant epilepsy who responded well to medicinal cannabis (and medicinal cannabis alone), regulations in the UK came into force to reschedule cannabis‑derived medicinal products to schedule 2 of the Misuse of Drugs Regulations 2001 and to allow prescribing of  …

Drug Science gives evidence to the Health and Social Care Committee drugs policy inquiry

The UK Government Health and Social Committee invited submissions to review the current policy positions in the UK. Read Drug Science's written submission here, and watch the oral submissions given by several other leading UK drug policy and health organisations: Health and harms: What is the extent of health harms resulting from drug use? Prevention  …

Why medical cannabis is still out of patients’ reach—an essay by David Nutt

Cannabis is arguably the world’s oldest medicine, with evidence of such use from 3000 year old tombs in Egypt and Siberia. It had a place in Indian and Chinese medical writing from nearly as long ago. It didn’t enter the UK until the late 1600s, but by the 1800s it was widely used, sold over  …

DrugScience Symposium 'Cannabis medicines: from principle to practice. How can we maximise clinical research and benefits?'

Please download the conference background materials here, including: Meeting slides DrugScience report on medicinal cannabis DrugScience cannabis pre-review submitted to the WHO Expert Committee on Drug Dependence Summaries of international and American medicinal cannabis licensing The Chief Medical Officer and advisor to the UK government has recently agreed that cannabis is a medicine. It has  …

Harms of nicotine-containing products

Around the world, politicians are working to ban e-cigarette marketing, limit their nicotine content, prohibit use in public buildings, and even to ban them entirely. There remains a need for policy makers to become better informed of the relative harms of nicotine delivery systems in order to build a regulatory framework that minimises harm. The  …


DrugScience ketamine review

The first comprehensive review of the drug since its classification, DrugScience’s ketamine review highlighted harms such as neurological and bladder damage. Read it here


Drug harms in the UK

An assessment of the various harms of drugs used recreationally in the UK using multi-criteria decision analysis (MCDA) – a method that uses relevant experts’ knowledge and experience to assess the actual and relative harms – download the paper here. You can also download the raw data here. We wanted to assess drugs in terms  …